Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML
Chezi Ganzel1, Avraham Frisch2, Ofir Wolach3
1The Hematology and Bone Marrow Transplantation Department The Eisenberg Research and Development Authority Shaare Zedek Medical Center The Hebrew University of Jerusalem Jerusalem Israel.
Ejhaem
|August 6, 2026
Summary
CPX-351 (a liposomal formulation) showed mild cardiac changes in acute myeloid leukemia patients, similar to standard therapy. However, a significant portion experienced clinically relevant cardiac issues, warranting monitoring.
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- CPX-351 is a liposomal formulation of daunorubicin and cytarabine.
- While associated with reduced non-hematologic toxicity, its cardiac safety profile remains under investigation.
- Acute myeloid leukemia (AML) treatment requires careful consideration of cardiac risks.
Purpose of the Study:
- To prospectively evaluate the cardiac safety of CPX-351 in younger adults with AML.
- To assess changes in ejection fraction (EF) and global longitudinal strain (GLS) following CPX-351 induction therapy.
- To compare cardiac effects of CPX-351 with standard "7 + 3" chemotherapy.
Main Methods:
- Prospective assessment of ejection fraction (EF) and global longitudinal strain (GLS).
- Study population: Younger adults with AML undergoing single CPX-351-based induction.
- Comparison group: Standard "7 + 3" chemotherapy regimen.
Main Results:
- Median changes in EF and GLS were mild and comparable to standard "7 + 3" therapy.
- A notable 27% of patients developed clinically significant cardiac changes.
- Findings highlight potential cardiac risks despite initial mild median changes.
Conclusions:
- CPX-351 treatment in AML may be associated with clinically significant cardiac changes in a subset of patients.
- Prospective cardiac monitoring is recommended for patients receiving CPX-351.
- Further comparative studies are needed to fully define the cardiac safety of CPX-351 versus standard therapies.
Related Concept Videos
01:28Imaging Studies for Cardiovascular System V: CT
Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...